Company / Shareholders' Equity
NOVAVAX INC Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$127.8M
FY2025
5-year range
-$716.9M / $627.2M
FY2021-FY2025
Trend
+79.5%
vs FY2024
Sector context
#202 of 213
Health Care
What the data says
NOVAVAX INC reports negative total equity of -$128M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$128M in FY2025.
Improved from -$717M to -$128M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 213This company -$127.8M Sector average $2.5B
▼
-105.0% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity increased 79.5% year-over-year.
- Ranks #202 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2022.
- Lowest shareholders' equity in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$127.8M | +79.5% |
| FY2024 | -$623.8M | +13.0% |
| FY2023 | -$716.9M | -214.3% |
| FY2022 | $627.2M | +278.4% |
| FY2021 | -$351.7M | -156.1% |
| FY2020 | $627.2M | +716.5% |
| FY2019 | -$101.7M | -1734.3% |
| FY2018 | -$5.5M | -101.9% |
| FY2017 | $292.7M | +27.5% |
| FY2016 | $229.6M | +13.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026